Compare BioNTech SE - ADR (BNTX) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Nuscale Power Corporation — how do they compare? BioNTech SE - ADR trades at $93.34 (market cap $23.31B), while Nuscale Power Corporation trades at $9.65 (market cap $4.06B). The key difference: BioNTech SE - ADR is far larger — about 5.7× Nuscale Power Corporation's market cap, and BioNTech SE - ADR is trading nearer its 52-week high, Nuscale Power Corporation nearer its low. Which is the better fit depends on your goals.
| BNTX | SMR | |
|---|---|---|
Market Cap | $23.31B | $4.06B |
Sector | Health | Utilities |
52-Week High | $119.34 | $53.43 |
52-Week Low | $83.89 | $7.59 |
Enterprise Value | $6.60B | $2.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.
The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.
NuScale Power (SMR) trades at $9.76, up 6.32% in the last session, with a bullish technical signal from moving averages. The company reported a net loss of $355.79 million in 2025 on revenue of $31.48 million, with negative margins, while analyst consensus is a Buy with a $10.50 price target. Recent news highlights regulatory progress and AI-driven power demand as growth catalysts.
Outlook hinges on commercial deployment of small modular reactors, offering high upside if execution succeeds, but risks include persistent losses, revenue volatility, and project delays. The stock presents speculative growth potential amid significant operational and financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
